Eravacycline, the firstfour years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022

Ashlan J.Kunz Coyne, Sara Alosaimy, Kristen Lucas, Abdalhamid M. Lagnf, Taylor Morrisette, Kyle C. Molina, Alaina DeKerlegand, Melanie Rae Schrack, S. Lena Kang-Birken, Athena L.V. Hobbs, Jazmin Agee, Nicholson B. Perkins, Mark Biagi, Michael Pierce, James Truong, Justin Andrade, Jeannette Bouchard, Tristan Gore, Madeline A. King, Benjamin M. PullingerKimberly C. Claeys, Shelbye Herbin, Reese Cosimi, Serina Tart, Michael P. Veve, Bruce M. Jones, Leonor M. Rojas, Amy K. Feehan, Marco R. Scipione, Jing J. Zhao, Paige Witucki, Michael J. Rybak

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Eravacycline, the firstfour years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science